What helps. What might. What’s still being tested.

What canine lifespan research tells us about body fat, muscle and feeding—and why lighter is not always healthier.

Calories, protein, completeness and preparation matter more than a diet label alone. Here is how to evaluate the food your dog actually eats.

How protein quality, daily intake and calories affect muscle maintenance—especially when an older dog starts eating less.

Why regular movement matters, what canine research supports, and how to think about variety, progression and recovery without inventing a universal prescription.

Why muscle loss can hide behind a normal weight, and how nutrition, movement and early recognition fit together.

Why regular brushing matters, what chews can add, and why a clean-looking tooth is not the same as a healthy mouth.

How examinations, baseline records and targeted screening can uncover problems before they are obvious, without treating every abnormal result as disease.

Why vaccination and parasite prevention belong in a healthspan plan—and how geography, travel and individual risk change the details.

The strongest canine evidence is for particular clinical uses, especially osteoarthritis—not a general promise of longer life.

Dogs can absorb supplemental creatine. Whether it reliably improves strength, muscle or healthy ageing is a different question.

Why low taurine can matter in some dogs, and why correcting deficiency is different from supplementing every healthy dog for longevity.

Glucosamine, marine lipids and collagen do not share one evidence base. Compare the formulation and the outcome, not just the joint-health label.

What enrichment research says about learning and wellbeing—and why enjoyable, achievable challenges are more useful than constant stimulation.

Sleep supports normal function, but disrupted rest can also reveal pain or cognitive change. Here is what the dog research can tell us.

Why a personal trend can be useful, how collection context changes interpretation, and where biomarker enthusiasm can get ahead of clinical value.

Canine studies show absorption and biological effects. Here is why those findings are interesting—and what they do not yet tell an owner.

The mitophagy mechanism and human endurance findings are interesting. Direct evidence for an oral muscle benefit in dogs is still missing.

Why this dietary compound attracts interest, what a mouse lifespan study found, and where the evidence stops for dog owners.

Controlled Beagle studies now go beyond human extrapolation. The strain, preparation and experimental diet are essential to understanding the results.

NAD+ biology is important. The evidence for supplementing its precursors needs to be separated into exposure, biomarkers, function and clinical benefit.

A senior-dog combination trial offers an interesting cognitive signal—but it does not prove that senescent-cell clearance extends canine healthspan.

What the early cardiac studies, safety observations and TRIAD trial do—and do not—establish for an ageing dog.

The biological rationale, development milestones and unanswered questions behind an investigational drug for larger dogs.

What the STAY study and FDA development milestones tell us, without confusing progress with proven lifespan extension.

Dog pharmacokinetic and safety studies exist. That is different from demonstrating that BPC-157 heals a canine tendon, ligament or digestive condition.

TB-500, thymosin beta-4 and related fragments are often treated as interchangeable. That shortcut can turn a real experiment into the wrong treatment claim.

Mouse performance results make this mitochondrial peptide interesting. Human exercise measurements and canine treatment claims need to stay separate.

Why the exact peptide, disease setting and outcome matter—and why older thymus studies do not establish modern canine anti-ageing use.

What the cell and mouse experiments show, why maximum lifespan is not average lifespan, and what remains unknown for dogs.

Canine trials offer indication-specific signals. Cell source, preparation, route and follow-up matter far more than the phrase 'regenerative medicine'.

Why treating a defined genetic defect is not the same challenge as safely changing the ageing trajectory of an otherwise healthy dog.